Overview

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with advanced malignant mesothelioma of the pleura. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Sunitinib